Kabra Drugs Limited, a active public limited company, was established on 22 August 1989 in Indore, Madhya Pradesh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L02423MP1989PLC005438. Registered under ROC Roc Gwalior. it is listed on BSE: 524322. It has an authorized capital of ₹40.00 Cr and a paid-up capital of ₹23.71 Cr.
It upholds a compliant status. Employing 37 professional, Its leadership includes Kuniamuthur Nanjappan Anand (Director), Anand Anitha (Director), Nanjappan Aravind (Additional Director). Past directors included Shyam Kabra, Rajendra Kumar Bordia, Shashikant Bapat. It holds no open charges and ₹1.99 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 208 Swadesh Bhavan,, 2 Press Complex, Ab Road, Indore, Madhya Pradesh, 452011.
L02423MP1989PLC005438
005438
22 August 1989
₹40.00 Cr
₹23.71 Cr
Roc Gwalior
Listed (BSE: 524322)
Active
Explore comprehensive insights into Kabra Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kuniamuthur Nanjappan Anand | Director | 09 Jun 2022 | Current |
| Anand Anitha | Director | 14 Jul 2022 | Current |
| Nanjappan Aravind | Additional Director | 14 Aug 2024 | Current |
| Ritu Tiwari | Additional Director | 08 Oct 2025 | Current |
| Nikita Sinha | Additional Director | 08 Oct 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Managing Director | 23 Aug 2018 | Past |
| Pramod Abcsdd | Director | 07 Apr 2017 | Past |
| Pramod Abcsdd | Director | 27 Aug 2008 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Director | 10 Jul 2018 | Past |
| Pramod Abcsdd | Director | 15 Oct 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Kabra Drugs Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2023, Kabra Drugs had a public holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹19,900,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2014 | Religare Finvest Limited | ₹1.51 Cr | Satisfied |
| 13 Nov 2010 | Bank Of India | ₹4.80 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Kabra Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Kabra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kabra Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Pavanasam was appointed as a Cfo was appointed as a Cfo on 13 Oct 2025 & has been associated with this company since 2 months 11 days . was completed.
Progress on Ritu Tiwari was appointed as a Additional Director was appointed as a Additional Director on 08 Oct 2025 & has been associated with this company since 2 months 16 days . was documented.
Progress on Nikita Sinha was appointed as a Additional Director was appointed as a Additional Director on 08 Oct 2025 & has been associated with this company since 2 months 16 days . was documented.
The activity Kabra Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
Kabra Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior. was recorded as a recent event.
Nanjappan Aravind was appointed as a Additional Director was appointed as a Additional Director on 14 Aug 2024 & has been associated with this company since 1 year 4 months . was recorded as a recent event.
The Board has accepted resignation of Mr. Rajendra Kumar Bordia from the Board of the Company..
The CIN of Kabra Drugs Limited is L02423MP1989PLC005438.
Kabra Drugs Limited is headquartered at 208 Swadesh Bhavan,, 2 Press Complex, Ab Road, Indore, Madhya Pradesh, 452011.
Kabra Drugs Limited was incorporated on 22 August 1989.
The current directors of Kabra Drugs Limited are
The primary industry of Kabra Drugs Limited is Manufacturing.
Kabra Drugs Limited is listed. It is listed on BSE: 524322.
The authorized capital of Kabra Drugs Limited is ₹40.00 Cr, and the paid-up capital is ₹23.71 Cr.
The compliance status of Kabra Drugs Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX